Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer

Eur J Med Chem. 2023 Dec 15:262:115925. doi: 10.1016/j.ejmech.2023.115925.

Jing-Yi Zhang ¹, Li-Jie Zhao ², Ya-Tao Wang ³

Affiliations

1 College of Chemistry and Chemical Engineering, Zhengzhou Normal University, 450044, China.
2 The Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, United States. Electronic address: [email protected].
3 First People's Hospital of Shangqiu, Henan Province, Shangqiu, 476100, China; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China. Electronic address: [email protected].

PMID: 37948954 DOI: 10.1016/j.ejmech.2023.115925

Abstract

Prostate Cancer is a prevalent form of Cancer that primarily affects men, with a high incidence and mortality rate. It is the second most common Cancer among males, following lung Cancer. Typically occurring in individuals aged 50 and above, this malignant tumor originates from abnormal cells in the prostate tissue. If left untreated, it can spread to nearby tissues, lymph nodes, and even bones. Current treatment methods include surgery, radiotherapy, and chemotherapy. However, these treatments have certain limitations and side effects. Therefore, researching and developing new small-molecule drugs to treat prostate Cancer is of great significance. In recent years, many small-molecule drugs have been proven to have therapeutic effects on prostate Cancer. The purpose of this review is to give a comprehensive look at the clinical uses and synthetic methods of various significant small-molecule drugs that have been approved to treat prostate Cancer, to facilitate the development of more powerful and innovative drugs for the effective control of prostate Cancer.

Keywords

Clinical applications; Drugs; Prostatic cancer; Synthesis.

Name
Email *

	Sorry, but the email address you supplied was invalid.